News & Events zu Sight Sciences Inc (SGHT)SGHTSight Sciences Inc

Sight Sciences TearCare System Receives FDA Expanded Indication

Sight Sciences announced that, effective August 18, the FDA updated the TearCare System Indications for Use to state: "The Sight Sciences TearCare System is a thermal-activated gland expression therapy that improves meibomian gland function in adult patients with evaporative dry eye disease due to meibomian gland dysfunction, when used in conjunction with manual expression of the meibomian glands." As a result of this expanded indication, TearCare is now the first and only treatment for MGD indicated to improve meibomian gland function in patients suffering from dry eye disease.

Sight Sciences Q2 Revenue Reaches $23.39M, Exceeds Expectations

Reports Q2 revenue $23.39M, consensus $21.69M. "We delivered a strong second quarter, with revenue growth accelerating to 20% year-over-year, and both business segments contributing meaningfully to the robust growth. Our performance reflects the growing interventional mindset across glaucoma and dry eye disease, the strength of our market-leading technologies, and the focus of our experienced commercial teams in partnering with customers to make interventional eye care the new standard of care," said Paul Badawi, Co-Founder and CEO of Sight Sciences. "Interventional Glaucoma revenue grew 8%, marking our fourth consecutive quarter of growth, and Interventional Dry Eye revenue nearly doubled sequentially for the second consecutive quarter and reached record quarterly sales. Importantly, we achieved this growth while maintaining strong gross margins and disciplined operating expense and cash management. Based on our year-to-date performance and business momentum, we are raising our 2026 revenue guidance, reducing our adjusted operating expense guidance, and we believe we are well positioned for the second half of the year."

Sight Sciences Raises 2026 Revenue Guidance to $88M-$92M

Consensus $86.08M. The company said, "Sight Sciences raised its revenue guidance for full year 2026 to range from $88 million to $92 million, representing year-over-year growth of 14% to 19%, versus prior revenue guidance of $83 million to $89 million. This revenue guidance includes Interventional Glaucoma revenue of $79 million to $81 million, representing growth of 4% to 7%, and Interventional Dry Eye revenue of $9 million to $11 million, compared to $1.6 million in 2025. The Company reduced its full year 2026 adjusted operating expenses guidance to range from $92 million to $94 million, representing an increase of 5% to 7% compared to 2025, versus prior adjusted operating expenses guidance of $93 million to $96 million. The increase compared to the prior year is primarily due to targeted investments in both business segments, including expanded market access efforts and additional commercial resources to scale the reimbursed dry eye market and the standalone glaucoma opportunity."